gip glp 1 agonist tirzepatide and glp 1 receptor agonists New Weight-Loss Drugs Are Poised to Upend Preventive Cardiology Care in Patients With Obesity Overweight It's important to study the – Tirzepatide, a dual GIP/GLP-1 receptor

Sonya Babu-Narayan, clinical director at the British Heart Foundation and consultant cardiologist, said: These intriguing results demonstrate that the benefits of medications like semaglutide on heart health go beyond weight loss alone. However, she commented: More research will be needed to unravel the other mechanisms of action behind the cardiovascular benefits beyond weight and fat loss, such as improvements in blood vessel health, control of blood pressure and blood sugar or inflammation

It is important to note that these technologies exist to improve mild-to-moderate skin laxity to a great extent

New Study Finds Tirzepatide Use Lowered Blood Pressure in Patients with Obesity The beneficial effects of tirzepatide (Mounjaro/Zepbound) extend beyond weight loss and glucose control, with results of a new study suggesting use of the first FDA-approved GLP-1/GIP receptor agonist could also help lower blood pressure

Challenges remain in safety, large-scale production, and clinical translation

Once you know how to inject semaglutide, its actually pretty easyand nearly pain-free